loading page

Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy
  • +5
  • Priya Chan,
  • Ashley Sabus,
  • Molly Hemenway,
  • Kathryn Chatfield,
  • Christina White ,
  • David Mirsky,
  • Nicholas Foreman,
  • Nathan Dahl
Priya Chan
University of Utah School of Medicine

Corresponding Author:[email protected]

Author Profile
Ashley Sabus
Children's Hospital Colorado
Author Profile
Molly Hemenway
University of Colorado - Anschutz Medical Campus
Author Profile
Kathryn Chatfield
University of Colorado - Anschutz Medical Campus
Author Profile
Christina White
University of Colorado - Anschutz Medical Campus
Author Profile
David Mirsky
University of Colorado - Anschutz Medical Campus
Author Profile
Nicholas Foreman
University of Colorado - Anschutz Medical Campus
Author Profile
Nathan Dahl
University of Colorado - Anschutz Medical Campus
Author Profile

Abstract

The event-free survival of pediatric low-grade gliomas is poor, and patients often require multiple treatment strategies. While MEK and RAF inhibitors are efficacious in early-phase trials, not all patients respond and many experience progression following completion of therapy. Evaluating combination therapies that may enhance efficacy or prolong disease stabilization is warranted. We report our institutional experience using concurrent trametinib and lenalidomide in the treatment of primary pediatric central and peripheral nervous system tumors. Two of four patients using this combination therapy experienced severe thromboembolic events necessitating discontinuation of therapy. This combination requires further investigation, and we urge caution if used.
25 Apr 2022Submission Checks Completed
25 Apr 2022Assigned to Editor
25 Apr 2022Submitted to Pediatric Blood & Cancer
24 May 2022Reviewer(s) Assigned
12 Jun 2022Review(s) Completed, Editorial Evaluation Pending
14 Jun 2022Editorial Decision: Revise Minor
02 Sep 2022Submission Checks Completed
02 Sep 2022Assigned to Editor
02 Sep 20221st Revision Received
13 Dec 2022Review(s) Completed, Editorial Evaluation Pending
13 Dec 2022Editorial Decision: Accept